Literature DB >> 18471921

Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation.

Amit Rawat1, Quamrul H Majumder, Fakhrul Ahsan.   

Abstract

This study tests the feasibility of large porous particles as long-acting carriers for pulmonary delivery of low molecular weight heparin (LMWH). Microspheres were prepared with a biodegradable polymer, poly(lactic-co-glycolic acid) (PLGA), by a double-emulsion-solvent-evaporation technique. The drug entrapment efficiencies of the microspheres were increased by modifying them with three different additivespolyethyleneimine (PEI), Span 60 and stearylamine. The resulting microspheres were evaluated for morphology, size, zeta potential, density, in vitro drug-release properties, cytotoxicity, and for pulmonary absorption in vivo. Scanning electron microscopic examination suggests that the porosity of the particles increased with the increase in aqueous volume fraction. The amount of aqueous volume fraction and the type of core-modifying agent added to the aqueous interior had varying degrees of effect on the size, density and aerodynamic diameter of the particles. When PEI was incorporated in the internal aqueous phase, the entrapment efficiency was increased from 16.22+/-1.32% to 54.82+/-2.79%. The amount of drug released in the initial burst phase and the release-rate constant for the core-modified microspheres were greater than those for the plain microspheres. After pulmonary administration, the half-life of the drug from the PEI- and stearylamine-modified microspheres was increased by 5- to 6-fold compared to the drug entrapped in plain microspheres. The viability of Calu-3 cells was not adversely affected when incubated with the microspheres. Overall, the data presented here suggest that the newly developed porous microspheres of LMWH have the potential to be used in a form deliverable by dry-powder inhaler as an alternative to multiple parenteral administrations of LMWH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18471921      PMCID: PMC2556066          DOI: 10.1016/j.jconrel.2008.03.013

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  36 in total

1.  How porosity and size affect the drug release mechanisms from PLGA-based microparticles.

Authors:  D Klose; F Siepmann; K Elkharraz; S Krenzlin; J Siepmann
Journal:  Int J Pharm       Date:  2006-02-28       Impact factor: 5.875

2.  Bone morphogenetic protein encapsulated with a biodegradable and biocompatible polymer.

Authors:  M Isobe; Y Yamazaki; S Oida; K Ishihara; N Nakabayashi; T Amagasa
Journal:  J Biomed Mater Res       Date:  1996-11

3.  Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs.

Authors:  Francesca Ungaro; Giuseppe De Rosa; Agnese Miro; Fabiana Quaglia; Maria Immacolata La Rotonda
Journal:  Eur J Pharm Sci       Date:  2006-05-22       Impact factor: 4.384

4.  Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes.

Authors:  Giuseppe De Rosa; Fabiana Quaglia; Maria Immacolata La Rotonda; Martine Appel; Huguette Alphandary; Elias Fattal
Journal:  J Pharm Sci       Date:  2002-03       Impact factor: 3.534

5.  Pulmonary delivery of low molecular weight heparins.

Authors:  Tianzhi Yang; Fatima Mustafa; Shuhua Bai; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

6.  Controlled delivery of therapeutics from microporous membranes. II. In vitro degradation and release of heparin-loaded poly(D,L-lactide-co-glycolide).

Authors:  M R Kreitz; J A Domm; E Mathiowitz
Journal:  Biomaterials       Date:  1997-12       Impact factor: 12.479

7.  Cationic stearylamine-containing biodegradable microparticles for DNA delivery.

Authors:  C Kusonwiriyawong; K Atuah; O H Alpar; H P Merkle; E Walter
Journal:  J Microencapsul       Date:  2004-02       Impact factor: 3.142

8.  Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.

Authors:  D A Scudiero; R H Shoemaker; K D Paull; A Monks; S Tierney; T H Nofziger; M J Currens; D Seniff; M R Boyd
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

9.  Feeding liquid, non-ionic surfactant and cyclodextrin affect the properties of insulin-loaded poly(lactide-co-glycolide) microspheres prepared by spray-drying.

Authors:  Fabiana Quaglia; Giuseppe De Rosa; Elena Granata; Francesca Ungaro; Elias Fattal; Maria Immacolata La Rotonda
Journal:  J Control Release       Date:  2003-01-17       Impact factor: 9.776

10.  Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes.

Authors:  Kavitha Koushik; Devender S Dhanda; Narayan P S Cheruvu; Uday B Kompella
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

View more
  27 in total

1.  Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH).

Authors:  Jahidur Rashid; Brijeshkumar Patel; Eva Nozik-Grayck; Ivan F McMurtry; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2017-02-07       Impact factor: 9.776

2.  Comparative studies on chitosan and polylactic-co-glycolic acid incorporated nanoparticles of low molecular weight heparin.

Authors:  Tianzhi Yang; Divine Nyiawung; Alexandra Silber; Jiukuan Hao; Leanne Lai; Shuhua Bai
Journal:  AAPS PharmSciTech       Date:  2012-09-28       Impact factor: 3.246

3.  Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.

Authors:  Susanne R Youngren-Ortiz; Nishant S Gandhi; Laura España-Serrano; Mahavir B Chougule
Journal:  Kona       Date:  2015-09-30       Impact factor: 2.897

4.  Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles.

Authors:  Chandan Thomas; Vivek Gupta; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2010-03-16       Impact factor: 4.200

5.  PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-β-cyclodextrin (PGE1-HPβCD) complex for the treatment of pulmonary arterial hypertension (PAH).

Authors:  Vivek Gupta; Marauo Davis; Louisa J Hope-Weeks; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2011-04-06       Impact factor: 4.200

Review 6.  Lactose engineering for better performance in dry powder inhalers.

Authors:  Yahya Rahimpour; Hamed Hamishehkar
Journal:  Adv Pharm Bull       Date:  2012-08-15

7.  Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator.

Authors:  Vivek Gupta; Fakhrul Ahsan
Journal:  Int J Pharm       Date:  2011-04-16       Impact factor: 5.875

8.  Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

Authors:  Jahidur Rashid; Ahmad Alobaida; Taslim A Al-Hilal; Samia Hammouda; Ivan F McMurtry; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2018-04-30       Impact factor: 9.776

9.  Aerosolized montelukast polymeric particles-an alternative to oral montelukast-alleviate symptoms of asthma in a rodent model.

Authors:  Brijeshkumar Patel; Nilesh Gupta; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2014-06-17       Impact factor: 4.200

10.  Chitosan-genipin microspheres for the controlled release of drugs: clarithromycin, tramadol and heparin.

Authors:  Ruth Harris; Elena Lecumberri; Angeles Heras
Journal:  Mar Drugs       Date:  2010-05-26       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.